Next Article in Journal
Cadmium Toxicity Effects on Histone Modifiers, Enzyme Activity and Adipokines in Human Adipose Tissue Cells
Previous Article in Journal
Recent Advances in Functionalized Nanomaterials: Design, Synthesis, Characterization, and Application
Previous Article in Special Issue
Amidine- and Amidoxime-Substituted Heterocycles: Synthesis, Antiproliferative Evaluations and DNA Binding
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 31
Issue 6
10.3390/molecules31061054
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ferrocenoylation of Uracil Derivatives: Study of Reaction Regioselectivity and Biological Activity

by
Jasmina Lapić
1,
Ivana Kuzman
1,
Ruža Frkanec
2,
Leo Frkanec
3 and
Senka Djaković
1,*
1
Faculty of Food Technology and Biotechnology, University of Zagreb, Pierottijeva 6, 10000 Zagreb, Croatia
2
Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, 10000 Zagreb, Croatia
3
Rudjer Bošković Institute, Bijenička 54, 10000 Zagreb, Croatia
*
Author to whom correspondence should be addressed.
Molecules 2026, 31(6), 1054; https://doi.org/10.3390/molecules31061054
Submission received: 12 February 2026 / Revised: 16 March 2026 / Accepted: 19 March 2026 / Published: 23 March 2026
(This article belongs to the Special Issue Ligand Binding to DNA and RNA, 2nd Edition)
Browse Figures
Versions Notes

Abstract

The N-ferrocenoylation of uracil was studied to evaluate regioselectivity and optimise preparation protocols. Regioselectivity was monitored under various reaction conditions, with particular attention paid to the effects of the solvent and the base. Reactions in DMF were regiospecific, yielding only the N1 product, while reactions in CH3CN produced both N1 and N1/N3 products, with ratios depending on the reaction conditions. The highest yield of N1/N3-diferrocenoyl uracil was achieved with an extended reaction time of 90 min using uracil and triethylamine. Optimised conditions were applied to C5-uracil derivatives, producing N1 and N1/N3 products. Regioselectivity and N-substitution were confirmed by NMR, and solvent effects were supported by quantum chemical calculations. The resulting ferrocene–pyrimidine conjugates exhibited oxidative and immunomodulatory activity, highlighting their biological potential.

1. Introduction

Medicinal chemistry, as a tool for developing and synthesising new compounds with potentials as drugs, has, for some time, focused on compounds that are hybrids of an organometallic fragment and another bioactive molecule. Organometallic fragments can introduce a wide range of new pharmacophores with unique interactions at target sites, leading to the discovery of drugs with novel mechanisms of action. One of the most interesting members of the metallocene family is ferrocene, which contains Fe(II) and two cyclopentadienyl ligands in a rigid sandwich structure. It is stable in physiological media and possesses lipophilic properties that allow it to cross cell membranes efficiently [1,2,3,4]. It can also be relatively easily derivatised, enabling its incorporation into various carriers [5,6,7,8,9]. Synthetic strategies for introducing ferrocene into pharmacophores involve either replacing the phenyl (ferrocyphene), alkyl (ferroquine), or heterocyclic ring of a known drug with a ferrocenyl group or attaching this group to various bioactive compounds, natural products, peptides, steroids, betulins, etc., via a functional group. Electronic delocalisation through the conjugation of ferrocenyl with bioactive molecules is favourable for oxidation, and our research group has linked the two fragments, ferrocene and nucleobase, via a carbonyl group. As both FcH derivatives and [Fc]+ have long been known for their anticancer and antimicrobial activities, one of the key parameters is the redox stability of both redox forms in biological media. Ferrocene chemistry involves the simple derivatisation of one or both cyclopentadienyl rings, which have stable redox forms (Fe(II) ↔ Fe(III)), and these forms can be easily interconverted under biological conditions without destruction or loss of function. The flexible structure and favourable physical properties of ferrocene drugs provide a solid foundation for developing sophisticated therapeutic strategies for precise, localised chemotherapy [10,11,12].
Nucleosides and their analogues play an important role in drug discovery and development due to their notable chemotherapeutic activities. In these drug molecules, the sugar moiety is often modified (e.g., in AZT or gemcitabine) or completely replaced (e.g., in abacavir and acyclovir) [13,14,15,16,17]. Studies on various ferrocene derivatives suggest that cancer cell cytotoxicity results from oxidation to the ferrocenium ion, which facilitates the formation of reactive oxygen species (ROS) that damage genetic material and induce apoptosis. In developing new biomolecules based on conjugates of ferrocene and nucleobases, the focus is on mimicking the parent structure of nucleosides and preserving the potential biological activity of the prepared compounds [18,19,20,21]. For the synthesis of nucleoside derivatives, the N-alkylation of nucleobases is often performed with different carbon electrophiles. However, the reactivity of nucleobases is often limited by their lower nucleophilicity and increased acidity of NH groups [13,22]. Replacing the sugar fragment of nucleosides with a redox-active, metal-containing ferrocenyl group could provide access to electron-conducting, self-assembling polymers, with applications in biology, medicine, and nanotechnology. The binding of substituents to the ferrocene molecule is enabled by the rotation of its cyclopentadienyl rings, and ferrocene acquires biological properties when a biological molecule such as a nucleobase is attached. This biological activity is an increasingly common research topic, with the first step being the synthesis of bioconjugates. Ferrocene is attached to the nitrogen base as an N-substituent, and the binding site determines the biological properties of the compound itself [23,24,25,26,27,28].
In our previous research on the preparation of organometallic ferrocene derivatives, we tested the regioselectivity of these reactions, which included both pyrimidine [29] and purine bases [30]. The bioconjugates were prepared by reacting ferrocenoyl chloride with sodium hydride in dimethylformamide. This reaction is regiospecific for pyrimidine derivatives, resulting in the formation of only N1 isomers [29], whereas purine derivatives exhibit different regioselectivity, with both N7 and N9 isomers formed. By introducing a suitable substituent at the C6 position of the purine ring, the ratio of the isomeric products N7 and N9 can be adjusted, i.e., the regioselectivity of the ferrocenoylation reaction can be modulated (Figure 1) [30].
This paper presents further research into the regioselectivity of the N-ferrocenoylation reaction of pyrimidine bases by varying reaction conditions. A model reaction on uracil was carried out to optimise the reaction conditions, focusing on the solvent and base, and their effects on regioselectivity were monitored. The optimised conditions were then applied to uracil derivatives bearing either electron-donating or electron-accepting groups at the C5 and C6 positions (Figure 2). The regioselectivity of the reactions was assessed using the 1H NMR technique. Density functional theory (DFT) calculations were performed to elucidate the mechanistic details underlying the observed regioselectivity. Pyrimidine-containing compounds are attractive candidates for drug development due to their diverse properties and unique structures, which can be readily modified [31]. This structural flexibility enables the design of a wide range of pyrimidine-based drugs with various biological activities and functions. The synthesised compounds were analysed for their oxidative and immunostimulatory activity.

2. Results and Discussion

2.1. Synthesis: Model Reaction, Regioselectivity, and DFT

Pyrimidine nucleobases and their derivatives substituted at the C5 position of the pyrimidine ring are characterised by potent biological activity and have been investigated as antiviral agents, nonradioactive fluorescent markers for DNA, and antitumor agents [26,32]. In addition to their biological activity, the hybrids also exhibit interesting electrochemical properties [33]. To mimic the natural structure of nucleosides and preserve the potential biological activity of the synthesised compounds, the ferrocene moiety must be selectively substituted at the N1 position of the base in place of the sugar moiety. Our research group has developed a one-step synthetic route for the preparation of the ferrocenoyl derivatives of pyrimidine and purine nucleobases containing a carbonyl group as a chemical spacer [29,30]. In previous studies, the reaction of pyrimidine bases (uracil, 5-fluorouracil, and thymine) with NaH and ferrocenoyl chloride in N,N-dimethylformamide (DMF) was investigated, and only an N1 product was observed [29]. In a similar reaction between a C6-substituted purine ring (R = NH2, Me, NHBz, and OBz) and ferrocenoyl chloride, two products were isolated, N7- and N9-ferrocenoylated compounds. We found that the ferrocenoylation of pyrimidine nucleobase derivatives is regiospecific, forming only N1 copolymers, whereas for purine derivatives, the reaction is regioselective, forming two products, N7 and N9, with the ratio in the reaction mixture depending on the C6 substituent on the purine ring [30]. In light of these results, a model reaction was performed on uracil to test the regioselectivity of the ferrocene–pyrimidine coupling reaction. In this work, the reaction progress was monitored under various conditions, including different acylating agents [ferrocenoyl chloride (1), ferrocenoylethyl carbonate (2), and ferrocenoyl benzotriazole (3)], solvents (N,N-dimethylformamide, acetonitrile, and 1,4-dioxane), bases (sodium hydride, potassium carbonate, and triethylamine), and reaction times.
The preparation of ferrocene nucleobase derivatives is based on coupling the organometallic moiety and the heterocyclic pyrimidine base via the carbonyl group as a bridge (Scheme 1). The starting compounds, ferrocenoyl chloride (1), ferrocenoylethyl carbonate (2), and ferrocenoyl benzotriazole (3), were synthesised according to previously described procedures [29,34]. Reaction of the nucleobase with NaH, K2CO3, or Et3N in DMF, CH3CN, or 1,4-dioxane leads to formation of a pyrimidine base salt. This is followed by the reaction of the pyrimidine base salt with the acylating agents, which proceeds rapidly and changes colour depending on the acylating agent used. The nucleobase salt is a strong nucleophile in reaction with acylating agents due to the negative charge on the nitrogen atom, which favours an SN2-like mechanism.
When ferrocenyl chloride (1) is used as an acylating agent with NaH as the base, and the reactions are carried out in DMF, only the N1 product is formed (Table 1, line 1). Replacing NaH with K2CO3 or Et3N in the same solvent also yields the N1 product only (Table 1, lines 2 and 3). Extending the reaction time to 60 or 90 min, regardless of the base used, results in the formation of the N1 product only, but with increased yield (Table 1, lines 4–9). The N-ferrocenylation reactions of uracil carried out in CH3CN result in a change in the reaction profile, with the formation of N1/N3-product 6a in addition to the N1 product 4a (Table 1, lines 10–18). The regioselectivity depends strongly on the type of base and the duration of the uracil salt-forming reaction. NaH and K2CO3 continue to favour the formation of product 4a, whereas Et3N reduces the selectivity and increases the proportion of 6a (Table 1, lines 10–18). Extending the reaction time of uracil with the base in CH3CN further promotes the formation of bis-products, with the highest yield obtained using Et3N after 90 min of reaction (Table 1, line 18). In 1,4-dioxane, the reaction is significantly less efficient, and the products (4a and 6a) were obtained only in the presence of Et3N and in low yields (Table 1, lines 21 and 22). In reactions with the other two acylating agents, ferrocenoyl ethyl carbonate (2) and ferrocenoyl benzotriazole (3) (Tables S1 and S2), the yields of N1 products (4a) are very low, and N1/N3 (6a) is not formed under any reaction conditions. Previous studies indicate the formation of the N1 isomer with a slight excess of the acylating agent, while increasing the excess leads to the formation of the N1/N3 product. Therefore, the course and regioselectivity of the reaction with a higher proportion of the acylating agent (ferrocenoyl chloride, 1) at a 1:2.4 ratio were investigated. In DMF, only one product, the N1 regioisomer, was formed, while in the reaction carried out in CH3CN, the yields of both products increased, but their ratio changed only slightly. The N-ferrocenoylation reaction was also tested using a twofold molar excess of the base relative to uracil. The results showed that neither the reaction yield nor the ratio of mono- to bis-ferrocenoylated products changed significantly.
The reaction with N1-protected uracil (N1 product, 4a) was also performed, yielding a significant amount of N1/N3 product (75%) using Et3N in CH3CN. These results indicate that the precise choice of solvent, base, and reaction time for uracil salt formation is crucial to control the regioselectivity and yield of the N-ferrocenoylation reaction of uracil.
The reactions were also monitored in situ by 1H NMR spectroscopy to determine the proportion of each product. The experiment involved continuous monitoring of the reaction from the first minute to completion, with the fraction of regioisomers formed determined from the integrals of the peaks assigned to each product. First, the progress of the reaction between ferrocenoyl chloride (1) and uracil, using NaH, was monitored in DMF-d7. During this reaction, only the formation of the N1 product (4a) was observed (Figure 3).
The reaction between ferrocenoyl chloride (1) and Et3N as the base in CH3CN as the solvent was also monitored in situ by 1H NMR spectroscopy. At the start of the reaction, the chemical shifts in both products, N1 (4a) and N1/N3 (6a), are visible on the spectrum, and their proportions do not change significantly during the remainder of the reaction (Figure 4). Chemical shifts characteristic of uracil compounds are also present in the spectrum. These NMR studies indicate that the reactions are very fast and occur instantaneously. This experiment confirmed the synthetic results and the proportion of individual isomers in the reaction mixture.
The percentage of products formed can be calculated from the 1H NMR spectrum (Figure 5). In the reaction between ferrocenoyl chloride (1) and uracil, carried out in CH3CN with Et3N as the base and with a prolonged reaction time of 90 min, 76% of N1-ferrocenoyl uracil (4a) and 24% of N1/N3-diferrocenoyl uracil (6a) were obtained.
To rationalise the mechanism underlying the regioselective reaction in DMF, quantum chemical calculations were performed. It is known that DMF can act as an oxygen nucleophile [35]. We have previously observed similar reactivity with DMSO, which acts as an oxygen nucleophile in the analogous chemistry of purine–ferrocenoyl conjugates [30,36]. In our case, DMF undergoes an SN2-like reaction with ferrocenoyl chloride (1) (Scheme 2). The calculated energy barrier for this reaction is only 107.6 kJ/mol, which can be easily overcome at slightly elevated temperatures or even at room temperature. The corresponding transition state structure TSI is characterised by simultaneous O–C bond formation and C–Cl bond breaking (Scheme 2). The reaction is endergonic by 48.6 kJ/mol, resulting in the formation of the reactive intermediate [FcCOOCHN(Me)2]+ (I).
This cationic form I is susceptible to nucleophilic attack by the uracil anion, deprotonated at either the N1 or N3 position. Thus, in the second step, the reactive intermediate I undergoes a reaction in which an N–C bond is formed, followed by the elimination of a DMF molecule. The transition state structure TS1, which connects the N1 uracil anion and its ferrocenoylated form 4a, is more than 30 kJ/mol more stable than the corresponding transition state structure TS3 for the competing process at the N3 position of the uracil anion. As shown earlier, no significant energy difference between the two products 4a and 4a’ was calculated, supporting the claim that regioselectivity is governed by the kinetic profile of the two reactions.
A similar observation was reported for reactions between pyrimidine base anions (at the N1 or N3 position) and a series of acyl chlorides: the regioselectivity in the ferrocenoylation of nucleobases was kinetically controlled [29]. Here, we demonstrate that the solvent can influence the observed regioselectivity by forming a short-lived intermediate that determines the preference for the N1-reaction. Unlike DMF, CH3CN cannot produce a comparable regioselective outcome. Our computational results suggest that the reaction between FcCOCl and CH3CN does not lead to the formation of the intermediate required for regioselective differentiation between the two pathways. All attempts to optimise the expected intermediate resulted in separated reactants. Acetonitrile is a weak nucleophile and must be activated by metal complexes to enhance its reactivity [37]. This explains why the ferrocenoylation of uracil in acetonitrile yields a reaction mixture containing both N1- and N1/N3-products.

2.2. Regioselectivity of the C5 Coupling Reaction of Uracil Derivatives

In the continuation of the research, model reaction conditions were applied to the C5 derivatives of uracil to examine the regioselectivity of these reactions. The groups attached to the C5 position of uracil can be electron-withdrawing or electron-donating, which may affect the course and regioselectivity of the reactions. Two reactions were carried out using ferrocenoyl chloride (1) as the acylating agent, referred to as method A and method B (Table 2). Method A used NaH as the base, with reactions performed in DMF, while method B used Et3N as the base and CH3CN as the solvent. The reactions demonstrated the regiospecificity of method A for uracil and its C5 derivatives. In all tested reactions, only the N1 product (4a–f) was formed (Table 2, rows 1–6), as confirmed by NMR studies.
In the reactions carried out with Et3N as the base in CH3CN (method B), two products were isolated in all cases: N1 products 4a–f, obtained as red crystals in yields of 23–59%, and N1/N3 products 6a–f, obtained as dark red crystals in yields of 22–35% (Table 2, lines 7–12). The results show that when an electron-donating group (CH3) is attached at the C5 position, the proportion of the N1 isomer is significantly higher than that of N1/N3 isomers (74:26, Table 2, line 8). However, when an electron-accepting group is located at the C5 position, the ratio changes, and both isomers are formed in approximately similar proportions (Table 2, lines 9–12). It can also be concluded that the electronegativity and size of the halogen atoms at the C5 position do not have a major influence on the regioselectivity of these reactions (Table 2).
The reaction of N-ferrocenoylation with 6-methyluracil (5) was attempted using both methods A and B, but no reaction occurred; neither N1 nor N1/N3 products were formed. The lack of reaction can primarily be attributed to the steric effect of the electron-donating group at the C6 position.

2.3. Biological Evaluation of Ferrocene–Pyrimidine Conjugates

2.3.1. Acellular ROS Activity Testing

The ROS-inducing activity of the compounds measures their ability to increase the formation of reactive oxygen species (ROS), which can damage biomolecules and cellular structures, leading to cytotoxicity and cell death. A commonly used method for detecting ROS is the acellular fluorimetric measurement of the fluorescence intensity of the dye DCFH2-DA. This dye is initially non-fluorescent; it is deacetylated to DCFH2, which is then oxidised by ROS to form the fluorescent products DCF (2,7-dichlorofluorescein) and fluorescein. For acellular measurements, the diacetate form (DCFH2-DA) is chemically hydrolysed using NaOH and then added at specific concentrations to the tested compounds. DCFH2-DA can detect hydroxyl and peroxyl radicals, as well as hypochlorous acid and peroxynitrite—and, to a lesser extent, superoxide radical and hydrogen peroxide [38]. An increase in fluorescence intensity over time and with increasing concentration indicates enhanced ROS formation.
The results show that the fluorescence intensity increases over time, reaching a maximum at t = 90 min, and also increases with the analyte concentration (Figure 6). Compounds 4a (Fc-U) and 4b (Fc-T) showed a significant increase in fluorescence intensity. This ROS activity suggests the potential biological activity of these compounds as cytotoxic agents against tumour cell lines. In addition to their ROS-inducing capacity, the ferrocenoylated uracil derivatives were further evaluated using a fluorescence quenching assay (Figure S1), which revealed their ability to quench fluorescence. All compounds exhibit concentration-dependent fluorescence quenching. Although the differences in fluorescence quenching among the compounds are relatively modest, the observed activity confirms the presence of redox interactions, which align with their previously demonstrated oxidative activity.

2.3.2. Testing the Immunostimulatory Activity In Vivo

Our aim was to determine whether these compounds could stimulate or modulate the immune response in a living organism, which is critical for potential applications in antiviral or anticancer therapies. Tumour development and survival are regulated in a complex and often chaotic manner, involving interactions between cancer cells, normal stromal cells, and the host immune system [39]. However, tumours have evolved multiple mechanisms to evade immune surveillance and destruction. The identification and development of compounds that can upregulate the immune response holds great promise for enhancing cancer treatment and offers new opportunities in cancer therapy. The synthesis and various biological activities of ferrocene–pyrimidine conjugates have been described to date [40,41,42].
Based on the results of ROS activity measurements, the influence of Fc-U (4a), Fc-T (4b), and Fc-F-U (4c) on specific immune responses was investigated. Immunostimulatory activity was assessed in a mouse model to determine whether the synthesised compounds affect antigen-specific immune reactions (Figure 7a). Specifically, the ferrocene–pyrimidine conjugates were evaluated for their effects on the immune response against the model antigen ovalbumin (OVA). NIH/OlaHsd mice were immunised with OVA mixed with the test compounds. To assess the nature of the induced immune response in terms of Th1/Th2 polarisation, levels of Th1-associated IgG2a and Th2-associated IgG1 antibody isotypes were measured (Figure 7b,c). The results revealed a significant increase in IgG production in the sera of mice immunised with OVA mixed with compounds 4a, 4b, and 4c. Muramyl dipeptide (MDP) was used as a positive control. As expected, MDP triggered a predominantly Th2-oriented response, with a significant increase in IgG1 and only a marginal increase in IgG2a compared to the control group immunised with OVA in saline. Compounds 4a and 4b enhanced the humoral immune response and promoted the production of total anti-OVA antibodies to a greater extent than MDP. The production of IgG2a antibodies is typically associated with a Th1-type immune response, which is important for promoting cell-mediated immunity and is often linked to antitumor and antiviral activity. In this study, the observed significant increase in IgG2a levels in mice immunised with 4a and 4b conjugates suggests that these compounds may skew the immune response towards a Th1 profile. This indicates their relevance in therapeutic strategies aimed at enhancing cellular immune responses, such as cancer immunotherapy. Preliminary results from the OVA-specific IgG analysis demonstrated that the synthesised ferrocene–pyrimidine conjugates modulate the OVA-specific immune response and alter the IgG1/IgG2a ratio. Taken together with their ROS-inducing activity, these findings support the further investigation of these compounds for potential application in antitumor therapy.

3. Materials and Methods

3.1. General

The syntheses were carried out under argon atmosphere in dry solvents. Thin layer chromatography was performed on pre-coated Merck silica gel 60F-254 plates (Darmstadt, Germany) using an appropriate solvent system to monitor reaction progress and for comparison purposes, and spots were detected under UV light (254 nm). The products were purified by column chromatography (Fluka, Geneva, Switzerland, silica gel, 90 Å, 70-230 mesh) using CH2Cl2 and CH2Cl2/(CH3)2CO mixtures. The melting points were determined using a Buechi apparatus (Uster, Switzerland). IR spectra were recorded for CH2Cl2 solutions or KBr pastilles using a Bruker ALPHA-FT-IR spectrophotometer (Billerica, MA, USA). The standard 1H, 13C{1H} NMR spectra of DMSO-d6 and CDCl3 solutions were recorded with a Varian INOVA 400 spectrometer (Palo Alto, CA, USA). The spectrometer operated at 399.6 MHz (1H) and 100.5 MHz (13C). The chemical shifts in the 1H NMR and 13C NMR spectra were expressed in parts per million (ppm) and related to the residual resonances of the solvent. Elemental analysis was performed on a PerkinElmer 2400 Series II CHNS Analyzer (Waltham, MA, USA); the main standard is acetanilide.

3.2. Materials

All pyrimidine derivatives [R(C5) = H, CH3, F, Cl, Br, I], [R(C5) = H, R′(C6) = CH3] were purchased from Sigma-Aldrich (St. Louis, MO, USA).

3.3. Preparation of Substrates

Ferrocenoyl chloride (FcCOCl, 1) [29], ferrocenoyl ethyl carbonate (FcCOOCOOEt, 2) [29], and ferrocenoyl benzotriazole (FcCOOBt, 3) [31] were synthesised according to known procedure. The synthesis and spectral characterisation of compounds 4a–c were described in an earlier paper [29].

3.4. Optimisation of the Reaction Conditions for the N-Ferrocenoylation of Uracil for Table 1, Tables S1 and S2

Deprotonating agent (NaH or K2CO3 or TEA, 1.5 mmol) was added in portions to uracil (1 mmol) suspended in solvent (DMF, CH3CN or 1,4-dioxane, 3 mL). After stirring for 30–90 min at room temperature, FcCOCl (1) (1.2 mmol) or FcCOOCOOEt (2) or FcCOOBt (3) was added dropwise to the clear solution. The mixture was stirred for 30 min, then neutralised with a 10% aqueous solution of citric acid and extracted with CH2Cl2. The organic layer was washed with water, and the solvents were evaporated in vacuo. Subsequent purification by column chromatography or preparative thin-layer chromatography yielded N1- or/and N1/N3-ferrocenoylated pyrimidine bases as separate fractions (Table 1, Tables S1 and S2).

3.5. General Procedure for the Preparation of N1- or/and N1/N3-Ferrocenoylated C5 Derivatives of Pyrimidine Bases for Table 2

Method A: C5-substituted uracil derivatives (1 mmol) were suspended in 1 mL DMF, and NaH (1.5 mmol) was added with constant stirring for 90 min at room temperature. Subsequently, the previously prepared ferrocenoyl chloride (1) (1.2 mmol) was added to the reaction mixture. After stirring for 30 min at room temperature, the reaction mixture was neutralised by adding 10% citric acid solution and extracted with CH2Cl2. The organic layer was then washed with water until it was neutral, dried with Na2SO4 and evaporated to dryness on a rotary evaporator. The crude product was dissolved in CH2Cl2 and purified by column chromatography on silica gel with the eluent CH2Cl2/CH3COCH3 10:0.2. The column chromatography yielded a product, the red N1-regioisomer. The purified product is purified again by chromatography on a silica gel plate with the eluent CH2Cl2/CH3COCH3 10:0.1 (Table 2).
Method B: C5-substituted uracil derivatives (1 mmol) were suspended in 3 mL CH3CN, and (C2H5)3N (1.5 mmol) was added. The mixture was stirred constantly at room temperature for 90 min. Subsequently, the previously prepared ferrocenoyl chloride (1) (2.4 mmol) was added to the reaction mixture. After stirring for 30 min at room temperature, the reaction mixture was neutralised by adding 10% citric acid solution and extracted with CH2Cl2. The organic layer was then washed with water until neutral, dried with Na2SO4, and evaporated to dryness on rotary vapour. The crude product was dissolved in CH2Cl2 and purified by column chromatography on silica gel with the eluent CH2Cl2/CH3COCH3 10:0.2. Two products were obtained by column chromatography: N1- and N1/N3-products. The purified products are purified again, each separately, by chromatography on a silica gel plate in the system CH2Cl2/CH3COCH3 10:0.2 (Table 2).

3.6. Characterisation of Products

N1/N3-diferrocenoyl uracil (6a): Red crystals, m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:1) showed Rf = 0.70. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.68 (d, JH,H = 8.1 Hz, 1H; C6-H), 5.92 (d, JH,H = 8.2 Hz, 1H; C5-H), 4.89 (s, 2H; CH-Fc), 4.77 (s, 2H; CH-Fc), 4.68 (s, 2H; CH-Fc), 4.63 (s, 2H; CH-Fc), 4.38 (s, 5H; Cp-H), and 4.29 (s, 5H; Cp-H) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 172.3 (FcCO), 161.5 (C4), 147.8 (C2), 139.1 (C6), 102.9 (C5), 73.9 (CH-Fc), 73.7 (CH-Fc), 73.5 (CH-Fc), 73.4 (CH-Fc), 71.9 (Cq-Fc), 71.0 (Cp), and 70.9 (Cp) ppm. IR (CH2Cl2): ῦmax = 3055 (w, CH, Fc), 1693 (s, C=O), 1438 (w, purine ring breathing), and 1266 (m, C–N) cm−1. Elemental analysis calcd (%) for C26H20Fe2N2O4: C 58.24, H 3.76, and N 5.23; found: C 58.44, H 3.75, and N 5.37.
N1/N3-diferrocenoyl thymine (6b): Red-orange crystals m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:0.2) showed Rf = 0.75. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.53 (s, 1H; C6-H), 4.88 (pt, 2H; CH-Fc), 4.76 (pt, 2H; CH-Fc), 4.65 (t, 2H; CH-Fc), 4.37 (s, 5H; Cp-H), 4.28 (s, 5H; Cp-H), and 2.04 (d, 3H; CH3) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 172.6 (FcCO), 172.6 (FcCO), 161.7 (C4), 148.0 (C2), 134.7 (C6), 111.5 (C5), 73.6 (CH-Fc), 73.3 (CH-Fc), 72.5 (CH-Fc), 72.3 (CH-Fc), 72.0 (Cq-Fc), 70.9 (Cp), 70.9 (Cp), and 12.7 (CH3) ppm. IR (CH2Cl2): ῦmax = 3082 (w, CH, Fc), 2943 (w, CH, Fc), 1688 (s, C=O), 1417 (s, purine ring breathing), and 1263 (C-CH3, ring) cm−1. Elemental analysis calcd (%) for C27H22Fe2N2O4: C 58.94, H 4.03, and N 5.09; found: C 55.61, H 3.75, and N 8.67.
N1/N3-diferrocenoyl-5-F-uracil (6c): Red crystals, m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:0.2) showed Rf = 0.71. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.81 (d, JH,H = 8.1 Hz, 1H; C6-H), 4.89 (s, 2H; CH-Fc), 4.78 (s, 2H; CH-Fc), 4.67 (s, 4H; CH-Fc), 4.39 (s, 5H, Cp-H), and 4.29 (s, 5H, Cp-H) ppm. 13C NMR (400 MHz, CDCl3, 25 °C): δ = 171.0 (FcCO), 170.5 (FcCO), 155.2 (C4), 146.1 (C2), 140.6 (C6), 122.9 (C5), 73.4 (CH-Fc), 73.3 (CH-Fc), 72.6 (CH-Fc), 71.3 (Cp), and 70.6 (Cp) ppm. IR (CH2Cl2): ῦmax = 3354 (w, NH), 2960 (w, CH, Fc), 1680 (s, C=O), and 1474 (s, purine ring breathing) cm−1. Elemental analysis calcd (%) for C26H19Fe2N2O4F: C 56.35, H 3.46, and N 5.06; found: C 56.36, H 3.49, and N 5.10.
N1-ferrocenoyl-5-Cl-uracil (4d): Red crystals m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:0.2) showed Rf = 0.20. 1H NMR (400 MHz, DMSO-d6, 25 °C): δ = 11.99 (s, 1H; N3-H), 8.46 (s, 1H; C6-H), 4.89 (s, 2H; CH-Fc), 4.74 (s, 2H; CH-Fc), and 4.35 (s, 5H, Cp-H) ppm. 13C NMR (100 MHz, DMSO-d6, 25 °C): δ = 171.9 (FcCO), 159.3 (C4), 148.6 (C2), 137.6 (C6), 108.7 (C5), 73.6 (CH-Fc), 71.5 (CH-Fc), 72.0 (Cq-Fc), and 70.7 (Cp) ppm. IR (KBr): ῦmax = 3464 (w, NH), 3158 (w, CH, Fc), 1698 (s, C=O), 1426 (s, purine ring breathing), and 863 (C–Cl) cm−1. Elemental analysis calcd (%) for C15H10FeN2O3Cl: C 50.39, H 2.82, and N 7.84; found: C 50.28, H 2.71, and N 7.77.
N1/N3-diferrocenoyl-5-Cl-uracil (6d): Red crystals m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:0.2) showed Rf = 0.73. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.91 (s, 1H; C6-H), 4.88–4.86 (m, 2H; CH-Fc), 4.77 (s, 2H; CH-Fc), 4.70 (s, 2H; CH-Fc), 4.67–4.65 (m, 2H; CH-Fc), 4.38 (s, 5H; Cp-H), and 4.30 (s, 5H; Cp-H) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 171.3 (FcCO), 171.2 (FcCO), 157.6 (C4), 147.1 (C2), 135.9 (C6), 110.2 (C5), 74.1 (CH-Fc), 73.7 (CH-Fc), 73.1 (CH-Fc), 72.7 (Cq-Fc), 72.0 (CH-Fc), 71.1 (Cp), and 71.1 (Cp) ppm. IR (CH2Cl2): ῦmax = 3052 (w, CH, Fc), 1699 (s, C=O), 1474 (s, purine ring breathing), and 863 (C–Cl) cm−1. Elemental analysis calcd (%) for C26H19Fe2N2O4Cl: C 58.35, H 3.58, and N 5.24; found: C 58.61, H 3.45, and N 5.17.
N1-ferrocenoyl-5-Br-uracil (4e): Red crystals m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:0.2) showed Rf = 0.22. 1H NMR (400 MHz, DMSO-d6, 25 °C): δ = 11.60 (s, 1H; N3-H), 8.40 (s, 1H; C6-H), 4.87 (s, 2H; CH-Fc), 4.73 (s, 2H; CH-Fc), and 4.34 (s, 5H; Cp-H) ppm. 13C NMR (100 MHz, DMSO-d6, 25 °C): δ = 172.2 (FcCO), 159.8 (C4), 149.2 (C2), 140.2 (C6), 97.9 (C5), 74.1 (CH-Fc), 73.4 (CH-Fc), 72.6 (Cq-Fc), 72.0 (CH-Fc), and 71.2 (Cp) ppm. IR (KBr): ῦmax = 3406 (w, NH), 3168 (w, CH, Fc), 2848 (w, CH), 1699 (s, C=O), and 1421 (s, purine ring breathing) cm−1. Elemental analysis calcd (%) for C15H10FeN2O3Br: C 44.81, H 2.51, and N 6.97; found: C 44.86, H 2.58, and N 6.91.
N1/N3-diferrocenoyl-5-Br-uracil (6e): Dark red crystals m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:0.2) showed Rf = 0.73. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 8.03 (s, 1H; C6-H), 4.87 (t, 2H; CH-Fc), 4.77 (s, 2H; CH-Fc), 4.70 (s, 2H; CH-Fc), 4.65 (pt, 2H; CH-Fc), 4.38 (s, 5H; Cp-H), and 4.30 (s, 5H; Cp-H) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 171.3 (FcCO), 171.2 (FcCO), 157.5 (C4), 147.3 (C2), 138.3 (C6), 98.1 (C5), 74.1 (CH-Fc), 73.6 (CH-Fc), 73.1 (Cq-Fc), 72.0 (CH-Fc), 71.1 (Cp), and 71.1 (Cp) ppm. IR (CH2Cl2): ῦmax = 3046 (w, CH, Fc), 1699 (s, C=O), and 1421 (s, purine ring breathing) cm−1. Elemental analysis calcd (%) for C26H19Fe2N2O4Br: C 50.77, H 3.11, and N 4.55; found: C 50.71, H 3.09, and N 54.61.
N1-ferrocenoyl-5-I-uracil (4f): Red crystals m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:0.2) showed Rf = 0.27. 1H NMR (400 MHz, DMSO-d6, 25 °C): δ = 11.75 (s, 1H; N3-H), 8.46 (s, 1H; C6-H), 4.88 (t, 2H; CH-Fc), 44.76 (t, 2H; CH-Fc), and 4.37 (s, 5H; Cp-H) ppm. 13C NMR (100 MHz, DMSO-d6, 25 °C): δ = 172.47 (FcCO), 161.3 (C4), 149.6 (C2), 144.9 (C6), 74.1 (CH-Fc), 72.5 (Cq-Fc), 72.0 (CH-Fc), 71.8 (C5), and 71.2 (Cp) ppm. IR (KBr): ῦmax = 3286 (w, NH), 3082 (w, CH, Fc), 1691 (s, C=O), and 1396 (s, purine ring breathing) cm−1. Elemental analysis calcd (%) for C15H12FeN2O3I: C 40.12, H 2.24, and N 6.23; found: C 40.01, H 2.29, and N 6.18.
N1/N3-diferrocenoyl-5-I-uracil (6f): Red crystals m.p. > 200 °C. TLC analysis (SiO2, CH2Cl2/acetone 10:0.2) showed Rf = 0.71. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 8.13 (s, 1H; C6-H), 4.88 (s, 2H; CH-Fc), 4.76 (s, 2H; CH-Fc), 4.71 (s, 2H; CH-Fc), 4.65 (m, 2H; CH-Fc), 4.38 (s, 5H; Cp-H), and 4.31 (s, 5H; Cp-H) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 171.1 (FcCO), 170.7 (FcCO), 157.9 (C4), 147.1 (C2), 143.0 (C6), 73.7 (CH-Fc), 73.2 (CH-Fc), 72.6 (Cq-Fc), 71.5 (CH-Fc), 70.7 (Cp), 70.6 (Cp), and 69.3 (C5) ppm. IR (CH2Cl2): ῦmax = 3063 (w, CH, Fc), 1713, 1682 (s, C=O), and 1444 (s, purine ring breathing) cm−1. Elemental analysis calcd (%) for C26H19Fe2N2O4I: C 47.17, H 2.89, and N 4.23; found: C 55.61, H 2.75, and N 4.28.

3.7. Density Functional Theory (DFT) Calculations

Geometries were optimised at the B3LYP level of theory, as implemented in the Gaussian 16 software package. The basis set for optimisation was standard Pople’s 6-31G(d) on non-metal atom centres, and the Stuttgart–Dresden–Bonn (SDD) basis set with effective core potential (ECP) was used for Fe. This DFT level has proven quite successful for transition-metal compounds and is well suited for the description of structures, energies, vibrational frequencies, and other properties. Harmonic frequencies were computed from analytical second derivatives. Gibbs energies of solvation were determined by using the SMD continuum solvation model at the same level of theory. The solvent relative permittivity of ε = 37.22 [N,N-dimethylformamide (DMF)] was used.
IRC calculations (intrinsic reaction coordinate, as implemented in Gaussian 16) [43] were performed to identify the minima connected through the transition state. The initial geometries used were that of the corresponding transition structures, and the paths were followed in both directions from that point. This method verified that a given transition state structure indeed connected the presumed energy minimum structures.

3.8. In Vivo Evaluation of Immunostimulatory Activity

Bovine serum albumin, Tween 20, monoclonal anti-chicken egg albumin (clone OVA-14 mouse IgG1 isotype), o-phenylenediamine dihydrochloride, and MDP were provided by Sigma-Aldrich, Schnelldorf, Germany. Horseradish peroxidase-conjugated goat anti-mouse IgG (HRP-anti-mouse IgG) was from Bio-Rad Laboratories (Hercules, CA, USA). Biotin-conjugated rat anti-mouse IgG1 and anti-mouse IgG2a monoclonal antibodies and streptavidin–peroxidase were from PharMingen, Becton Dickinson (San Diego, CA, USA). Chemicals for buffers and solutions were purchased from Kemika d.d. (Zagreb, Croatia). Ovalbumin was purchased from Serva Electrophoresis GmbH, Heidelberg, Germany. Details can be found in the Supplementary Materials.

4. Conclusions

The N-ferrocenoylation of uracil demonstrated that regioselectivity depends strongly on the choice of solvent. Reactions in DMF were regiospecific, yielding only the N1 product under all conditions tested, whereas reactions in CH3CN produced both N1 and N1/N3 products, with the relative proportions strongly influenced by the base and the duration of nucleobase salt formation. Computational studies confirmed that, in DMF, a short-lived reactive intermediate is stabilised, favouring nucleophilic attack at the N1 position, while in CH3CN, such an intermediate does not form, resulting in a mixture of regioisomers. Applying the optimised conditions to C5-substituted uracil derivatives showed that electron-donating groups increase the proportion of the N1-isomer, while electron-accepting groups result in more balanced N1 and N1/N3 ratios. Halogen substitution at the C5 position had minimal effect on regioselectivity. The synthesised ferrocenoylated uracil derivatives exhibited time- and concentration-dependent ROS generation, measurable fluorescence quenching, and immunomodulatory activity, indicating that their biological activity is closely linked to their redox properties. These findings highlight the importance of solvent and substituent effects in controlling regioselectivity, as well as the potential of ferrocene–pyrimidine conjugates as redox-active therapeutic agents, including applications in anticancer and immunomodulatory strategies.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules31061054/s1. 1. Table S1. Regioselectivity of reactions using FcCOOCOOEt (2); Table S2. Regioselectivity of reactions using FcCOOBt (3); 2. ELISA for qualitative and quantitative determination of anti-OVA IgG; 3. Acellular ROS activity testing [including Figure S1. Fluorescence quenching test using a 0.1 μM F-DA (fluorescein-diacetate solution)]; 4. IR and NMR Spectra; 5. XYZ Coordinates of optimised stationary points. Figure S1. Fluorescence quenching test using a 0.1 μM F-DA (fluorescein-diacetate solution). Results are shown for the tested compounds at concentrations of 62.5, 125, and 250 mgL−1; Figure S2. (a) 1H NMR and (b) 13C APT NMR of compd. 4d; Figure S3. (a) 1H NMR and (b) 13C NMR of compd. 4e; Figure S4. (a) 1H NMR and (b) 13C APT NMR of compd. 4f; Figure S5. (a) 1H NMR and (b) 13C NMR of compd. 6a; Figure S6. (a) 1H NMR and (b) 13C NMR of compd. 6b; Figure S7. (a) 1H NMR and (b) 13C APT NMR of compd. 6c; Figure S8. (a) 1H NMR and (b) 13C NMR of compd. 6d; Figure S9. (a) 1H NMR and (b) 13C NMR of compd. 6e; Figure S10. (a) 1H NMR and (b) 13C APT NMR of compd. 6f; Figure S11. IR spectra of compd. 4a i 6a; Figure S12. IR spectra of compd. 4b i 6b; Figure S13. IR spectra of compd. 4c i 6c; Figure S14. IR spectra of compd. 4d i 6d; Figure S15. IR spectra of compd. 4e i 6e; Figure S16. IR spectra of compd. 4f i 6f [44,45].

Author Contributions

Conceptualization, S.D.; methodology, J.L., I.K., R.F. and L.F.; formal analysis, J.L., I.K., R.F. and S.D.; investigation, J.L., I.K. and R.F.; resources, L.F.; writing—original draft preparation, J.L., R.F. and S.D.; writing—review and editing, S.D., J.L., R.F. and L.F.; visualisation, J.L. and S.D.; supervision, S.D.; funding acquisition, L.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Croatian Science Foundation (HRZZ), grant number IP-2016-06-1137 and IP-2025-02-8382.

Institutional Review Board Statement

All animal experiments were conducted in accordance with the Croatian Law on Animal Welfare (2017) and the EC Directive 2010/63/EU. Ethical approval was obtained from the Ethical Committee of the Institute of Immunology and the Directorate of Veterinary and Food Safety of the Ministry of Agriculture, Republic of Croatia (approval number: HR-POK-009).

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Acknowledgments

The authors acknowledge Valerije Vrček (University of Zagreb, Faculty of Pharmacy and Biochemistry) for performing the DFT calculations, which helped explain the regioselectivity of the tested model reaction. The authors would like to thank the Zagreb University Computing Centre (SRCE) for granting computational resources on the ISABELLA cluster.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Heinze, K.; Lang, H. Ferrocene-Beauty and Function. Organometallics 2013, 32, 5623–5625. [Google Scholar] [CrossRef]
  2. Singh, A.; Lumb, I.; Mehra, V.; Kumar, V. Ferrocene-appended pharmacophores: An exciting approach for modulating the biological potential of organic scaffolds. Dalton Trans. 2019, 48, 2840–2860. [Google Scholar] [CrossRef] [PubMed]
  3. van Staveren, D.R.; Metzler-Nolte, N. Bioorganometallic Chemistry of Ferrocene. Chem. Rev. 2004, 104, 5931–5985. [Google Scholar] [CrossRef] [PubMed]
  4. Sharma, B.; Kumar, V. Has Ferrocene Really Delivered Its Role in Accentuating the Bioactivity of Organic Scaffolds? J. Med. Chem. 2021, 64, 16865–16921. [Google Scholar] [CrossRef]
  5. Plażuk, D.; Vessières, A.; Hillard, E.A.; Buriez, O.; Labbé, E.; Pigeon, P.; Jaouen, G. A 3-Ferrocenophane Polyphenol Showing a Remarkable Antiproliferative Activity on Breast and Prostate Cancer Cell Lines. J. Med. Chem. 2009, 52, 4964–4967. [Google Scholar] [CrossRef] [PubMed]
  6. Gasser, G.; Metzler-Nolte, N. The potential of organometallic complexes in medicinal chemistry. Curr. Opin. Chem. Biol. 2012, 16, 84–91. [Google Scholar] [CrossRef]
  7. Liu, Z.-Q. Is it still worth renewing nucleoside anticancer drugs nowadays? Eur. J. Med. Chem. 2024, 264, 115987. [Google Scholar] [CrossRef]
  8. Tomar, V.; Kumar, P.; Sharma, D.; Joshi, R.K.; Nemiwal, M. Anticancer potential of ferrocene-containing derivatives: Current and future prospective. J. Mol. Struct. 2025, 1319, 139589. [Google Scholar] [CrossRef]
  9. Sharma, A.; Rana, R.; Kumar, N.; Jyoti; Khanna, A.; Gulati, H.K.; Pooja; Kaur, S.; Singh, J.V.; Singh Bedi, P.M. Remarkable contribution of ferrocene as anticancer agent: An updated review (2020–2024). Inorg. Chem. Commun. 2025, 175, 114155. [Google Scholar] [CrossRef]
  10. Ornelas, C.; Astruc, D. Ferrocene-Based Drugs, Delivery Nanomaterials and Fenton Mechanism: State of the Art, Recent Developments and Prospects. Pharmaceutics 2023, 15, 2044. [Google Scholar] [CrossRef]
  11. Astruc, D. Why is ferrocene so exceptional? Eur. J. Inorg. Chem. 2017, 2017, 6–29. [Google Scholar] [CrossRef]
  12. Neuse, E.W. Macromolecular ferrocene compounds as cancer drug models. J. Inorg. Organomet. Polym. Mater. 2005, 15, 3–31. [Google Scholar] [CrossRef]
  13. Soltani Rad, M.N.; Behrouz, S.; Asrari, Z.; Khalafi-Nezhad, A. A simple and regioselective one-pot procedure for the direct N-acylation of some purine and pyrimidine nucleobases via carboxylic acids using cyanuric chloride. Monatsh. Chem. 2014, 145, 1933–1940. [Google Scholar] [CrossRef]
  14. Marcantonio, E.; Guazzetti, D.; Coppa, C.; Battistini, L.; Sartori, A.; Bugatti, K.; Provinciael, B.; Curti, C.; Contini, A.; Vermeire, K.; et al. The chiral 5,6-cyclohexane-fused uracil ring-system: A molecular platform with promising activity against SARS-CoV-2. Eur. J. Med. Chem. 2025, 286, 117302. [Google Scholar] [CrossRef] [PubMed]
  15. Klarek, M.; Schäfer, T.; Gorski, A.; Dutkiewicz, N.; Hikisz, P.; Gapinska, M.; Trzybiński, D.; Woźniak, K.; Müller, J.; Kowalski, K. Luminescent Click-Pyrenyl Nucleosides: As Novel Building Blocks for Nucleic Acids: Synthesis, Photophysics, Confocal Microscopy Studies, and Oligonucleotide Conjugation. Eur. J. Org. Chem. 2025, 28, e202500559. [Google Scholar] [CrossRef]
  16. Körber, M.; Rühle, J.; Halter, F.; Mokhir, A. Hydrogen Peroxide-Responsive Aminoferrocene Prodrugs. Eur. J. Org. Chem. 2025, 28, e202500294. [Google Scholar] [CrossRef]
  17. Meng, Y.; Sun, N.; Liang, L.; Yu, B.; Chang, J. 2′-Fluorinated nucleoside chemistry for new drug discovery: Achievements and prospects. Natl. Sci. Rev. 2024, 11, nwae331. [Google Scholar] [CrossRef]
  18. Chellan, P.; Sadler, P.J. Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments. Chem. Eur. J. 2020, 26, 8676–8688. [Google Scholar] [CrossRef]
  19. Biegański, P.; Godel, M.; Riganti, C.; Fábio Kawano, D.; Kopecka, J.; Kowalski, K. Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. Bioorganic Chem. 2022, 119, 105514. [Google Scholar] [CrossRef]
  20. Ji, C.; Dong, R.; Zhang, P.; Tao, R.; Wang, X.; Dai, Q.; Liu, X.; Yuan, X.A.; Zhang, S.; Yue, M.; et al. Ferrocene-modified half-sandwich iridium(III) and ruthenium(II) propionylhydrazone complexes and anticancer application. J. Inorg. Biochem. 2024, 257, 112586. [Google Scholar] [CrossRef]
  21. Savani, C.J.; Pateliya, R.B.; Srivastava, R.R.; Vennapu, D.R.; Nath, S.; Singh, A.K.; Roy, H.; Rajak, D.K.; Singh, V.K. Dependence of anti-proliferative activity on chirality and redox potentials (Eh) of new ferrocene derivatives: Synthesis, crystallographic, photophysical and in-silico study. J. Organomet. Chem. 2023, 1001, 122854. [Google Scholar] [CrossRef]
  22. Szlaużys, M.; Ostrowski, K.; Nowak, D.; Prukała, W.; Starzyk, J.; Jasiewicz, B.; Mrówczyńska, L. Hybrid Uracil Derivatives with Caffeine and Gramine Obtained via Click Chemistry as Potential Antioxidants and Inhibitors of Plant Pathogens. Molecules 2025, 30, 2714. [Google Scholar] [CrossRef]
  23. Skiba, J.; Yuan, Q.; Hildebrandt, A.; Lang, H.; Trzybiński, D.; Woźniak, K.; Balogh, R.K.; Gyurcsik, B.; Vrček, V.; Kowalski, K. Ferrocenyl GNA Nucleosides: A Bridge between Organic and Organometallic Xeno-nucleic Acids. ChemPlusChem. 2018, 83, 77–86. [Google Scholar] [CrossRef] [PubMed]
  24. Liu, M.; Zhang, J. Synthesis and fluorescence of pyrazolines substituted with pyrimidine and ferrocene subunits. Heterocycl. Commun. 2016, 22, 31–35. [Google Scholar] [CrossRef]
  25. Kowalski, K.; Koceva-Chyla, A.; Pieniazek, A.; Bernasinska, J.; Skiba, J.; Rybarczyk-Pirek, A.J.; Jozwiak, Z. The synthesis, structure, electrochemistry and in vitro anticancer activity studies of ferrocenyl-thymine conjugates. J. Organomet. Chem. 2012, 700, 58–68. [Google Scholar] [CrossRef]
  26. Palasz, A.; Cież, D. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications. Eur. J. Med. Chem. 2015, 97, 582–611. [Google Scholar] [CrossRef]
  27. Wang, R.; Chen, H.; Yan, W.; Zheng, M.; Zhang, T.; Zhang, Y. Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships. Eur. J. Med. Chem. 2020, 190, 112109. [Google Scholar] [CrossRef] [PubMed]
  28. Skiba, J.; Hirschfeld, M.; Lang, H.; Trzybiński, D.; Woźniak, K.; Gazecka, M.; Zmora, P.; Kowalski, K. Click-ferrocenyl nucleotides-synthesis, electrochemistry, and antiproliferative activity studies. J. Organomet. Chem. 2024, 1016, 123242. [Google Scholar] [CrossRef]
  29. Lapić, J.; Havaić, V.; Šakić, D.; Sanković, K.; Djaković, S.; Vrček, V. Ferrocenoyl-Substituted Pyrimidine Nucleobases: An Experimental and Computational Study of Regioselective Acylation of Uracil, Thymine, and 5-Fluorouracil. Eur. J. Org. Chem. 2015, 24, 5424–5431. [Google Scholar] [CrossRef]
  30. Toma, M.; Božičević, L.; Lapić, J.; Djaković, S.; Šakić, D.; Tandarić, T.; Vianello, R.; Vrček, V. Transacylation in Ferrocenoyl-Purines. NMR and Computational Study of the Isomerization Mechanism. J. Org. Chem. 2019, 84, 12471. [Google Scholar] [CrossRef]
  31. Boumi, S.; Moghimirad, J.; Amanlou, M.; Ostad, S.N.; Tavajohi, S.; Amini, M. Synthesis, evaluation of biological activity, docking and molecular dynamic studies of pyrimidine derivatives. Lett. Org. Chem. 2021, 18, 212–225. [Google Scholar] [CrossRef]
  32. Kaur, R.; Roychowdhury, T.; Kinarivala, N.; Kaur, K.; Sanduja, M.; Sharma, S. Recent Expansions in the Potential of Uracil Derivatives as Chemotherapeutic, Antimicrobial, and Antiviral Agents: A Review. ChemistrySelect 2025, 10, e202406021. [Google Scholar] [CrossRef]
  33. Havaić, V.; Djaković, S.; Lapić, J.; Weitner, T.; Šakić, D.; Vrček, V. Reduction Potential of Ferrocenoyl-Substituted Nucleobases. Experimental and Computational Study. Croat. Chem. Acta 2017, 90, 589–594. [Google Scholar] [CrossRef]
  34. Lapić, J.; Djaković, S.; Kodrin, I.; Mihalić, Z.; Cetina, M.; Rapić, V. Preparation and Conformation Analysis of N-(Ferrocenoyl)dipeptide Esters and Their 1-Acetyl Derivatives. Eur. J. Org. Chem. 2010, 13, 2512–2524. [Google Scholar] [CrossRef]
  35. Majid, M.; Heravi, M.G.; Mohammadkhani, L. Beyond a solvent: Triple roles of dimethylformamide in organic chemistry. RSC Adv. 2018, 8, 27832–27862. [Google Scholar] [CrossRef]
  36. Toma, M.; Zubčić, G.; Lapić, J.; Djaković, S.; Šakić, D.; Vrček, V. Ferrocenoyl-adenines: Substituent effects on regioselective acylation. Beilstein J. Org. Chem. 2022, 18, 1270–1277. [Google Scholar] [CrossRef]
  37. Kumagai, N.; Matsunaga, S.; Shibasaki, M. Cooperative Catalysis of a Cationic Ruthenium Complex, Amine Base, and Na Salt: Catalytic Activation of Acetonitrile as a Nucleophile. J. Am. Chem. Soc. 2004, 126, 13632–13633. [Google Scholar] [CrossRef]
  38. Gomes, A.; Fernandes, E.; Lima, J.L.F.C. Fluorescence probes used for detection of reactive oxygen species. J. Biochem. Biophys. Methods 2005, 65, 45–80. [Google Scholar] [CrossRef]
  39. Vinay, D.S.; Ryan, E.P.; Pawelec, G.; Talib, W.H.; Stagg, J.; Elkord, E.; Lichtor, T.; Decker, W.K.; Whelan, R.L.; Kumara, H.M.C.S.; et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 2015, 35, S185–S198. [Google Scholar] [CrossRef]
  40. Chopra, R.; De Kock, C.A.; Smith, P.; Chibale, K.; Singh, K. Ferrocene-pyrimidine conjugates: Synthesis, electrochemistry, physicochemical properties and antiplasmodial activities. Eur. J. Med. Chem. 2015, 100, 1–9. [Google Scholar] [CrossRef]
  41. Simenel, A.A.; Dokuchaeva, G.A.; Snegur, L.V.; Rodionova, A.N.; Ilyina, M.M.; Zykova, S.I.; Ostrovskaya, L.A.; Bluchterova, N.V.; Fomina, M.M.; Rikova, V.A. Ferrocene-modified thiopyrimidines: Synthesis, enantiomeric resolution, antitumor activity. Appl. Organomet. Chem. 2011, 25, 70–75. [Google Scholar] [CrossRef]
  42. Das, S.; Borkotoky, S.; Rymbai, M.; Borah, V.V.; Roy, J.D.; Kaping, S.; Helissey, P.; Vishwakarma, J.N. Novel ferrocene-pyrazolo [1,5-a]pyrimidine hybrids: A facile environment-friendly regioselective synthesis, structure elucidation, and their antioxidant, antibacterial, and anti-biofilm activities. J. Chem. Sci. 2022, 134, 79. [Google Scholar] [CrossRef]
  43. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Petersson, G.A.; Nakatsuji, H.; et al. Gaussian, version 16; Revision C.01; Gaussian, Inc.: Wallingford, CT, USA, 2016.
  44. Habjanec, L.; Frkanec, R.; Halassy, B.; Tomašić, J. Effect of liposomal formulations and immunostimulating peptidoglycan monomer (PGM) on the immune reaction to ovalbumin in mice. J. Liposome Res. 2006, 16, 1–16. [Google Scholar] [CrossRef] [PubMed]
  45. Halassy, B.; Krstanović, M.; Frkanec, R.; Tomašić, J. Adjuvant activity of peptidoglycan monomer and its metabolic products. Vaccine 2003, 21, 971. [Google Scholar] [CrossRef] [PubMed]
Molecules 31 01054 g001
Figure 1. Structure of N7- and N9-ferrocenoyl purine derivatives.
Figure 1. Structure of N7- and N9-ferrocenoyl purine derivatives.
Molecules 31 01054 g001
Molecules 31 01054 g002
Figure 2. Structure of N1-, N3- and N1/N3-ferrocenoyl pyrimidine derivatives.
Figure 2. Structure of N1-, N3- and N1/N3-ferrocenoyl pyrimidine derivatives.
Molecules 31 01054 g002
Molecules 31 01054 sch001
Scheme 1. Ferrocenoylation of uracil derivatives; base: NaH or K2CO3 or Et3N; solvents: DMF or CH3CN or 1,4-dioxane.
Scheme 1. Ferrocenoylation of uracil derivatives; base: NaH or K2CO3 or Et3N; solvents: DMF or CH3CN or 1,4-dioxane.
Molecules 31 01054 sch001
Molecules 31 01054 g003
Figure 3. 1H{13C} NMR spectra of the reaction of ferrocenoyl chloride (1) and uracil in DMF-d7.
Figure 3. 1H{13C} NMR spectra of the reaction of ferrocenoyl chloride (1) and uracil in DMF-d7.
Molecules 31 01054 g003
Molecules 31 01054 g004
Figure 4. 1H{13C} NMR spectra of the reaction of ferrocenoyl chloride (1) and uracil in CH3CN-d3 with Et3N as base.
Figure 4. 1H{13C} NMR spectra of the reaction of ferrocenoyl chloride (1) and uracil in CH3CN-d3 with Et3N as base.
Molecules 31 01054 g004
Molecules 31 01054 g005
Figure 5. The fraction of N1 and N1/N3 products formed in the reaction of ferrocenoyl chloride (1) and uracil in CH3CN with Et3N as base (90 min of reaction).
Figure 5. The fraction of N1 and N1/N3 products formed in the reaction of ferrocenoyl chloride (1) and uracil in CH3CN with Et3N as base (90 min of reaction).
Molecules 31 01054 g005
Molecules 31 01054 sch002
Scheme 2. Proposed mechanism of the regioselective ferrocenoylation of uracil observed in DMF. All relative energies (ΔG, in kJ/mol; in parentheses) are calculated at the SMD-B3LYP/6-31G(d)/SDD level of theory in N,N-dimethylformamide (ε = 37.22) as a model solvent. ‡ = symbol for a transition state.
Scheme 2. Proposed mechanism of the regioselective ferrocenoylation of uracil observed in DMF. All relative energies (ΔG, in kJ/mol; in parentheses) are calculated at the SMD-B3LYP/6-31G(d)/SDD level of theory in N,N-dimethylformamide (ε = 37.22) as a model solvent. ‡ = symbol for a transition state.
Molecules 31 01054 sch002
Molecules 31 01054 g006
Figure 6. Acellular ROS activity for synthesised compounds and positive control, 6-methylpurine, with DCFH2-DA assay. Intensity of fluorescence increases with concentration of analysed substance as well as with time.
Figure 6. Acellular ROS activity for synthesised compounds and positive control, 6-methylpurine, with DCFH2-DA assay. Intensity of fluorescence increases with concentration of analysed substance as well as with time.
Molecules 31 01054 g006
Molecules 31 01054 g007
Figure 7. The effect of the tested compounds on the production of total anti-OVA IgGs as well as anti-OVA IgG1 and anti-OVA IgG2a in the sera of NIH/OlaHsd female mice (n = 6) after the second booster. Total anti-OVA IgG (a); anti-OVA IgG1 (b); and anti-OVA IgG2a (c). Experimental groups were as follows: 1. OVA; 2. OVA + MDP, 3. OVA + Fc-U (4a), 4. OVA + Fc-F-U (4c), and 5. OVA + Fc-T (4b). x denotes group mean value.
Figure 7. The effect of the tested compounds on the production of total anti-OVA IgGs as well as anti-OVA IgG1 and anti-OVA IgG2a in the sera of NIH/OlaHsd female mice (n = 6) after the second booster. Total anti-OVA IgG (a); anti-OVA IgG1 (b); and anti-OVA IgG2a (c). Experimental groups were as follows: 1. OVA; 2. OVA + MDP, 3. OVA + Fc-U (4a), 4. OVA + Fc-F-U (4c), and 5. OVA + Fc-T (4b). x denotes group mean value.
Molecules 31 01054 g007
Table 1. Regioselectivity of reactions using FcCOCl (1).
Table 1. Regioselectivity of reactions using FcCOCl (1).
LinesBaseSolventReaction Time/min4a
η (%)		6a
η (%)		4a:6a
1
2
3		NaH
K2CO3
Et3N		DMF3065
45
30		-
-
-
4
5
6		NaH
K2CO3
Et3N		6072
49
24		-
-
-
7
8
9		NaH
K2CO3
Et3N		9074
68
52		-
-
-
10
11
12		NaH
K2CO3
Et3N		CH3CN3041
5
20		-
-
3		-
-
87:13
13
14
15		NaH
K2CO3
Et3N		6060
17
19		4
3
14		94:6
85:15
62:38
16
17
18		NaH
K2CO3
Et3N		9045
62
42		7
3
27		87:13
96:4
60:40
19
20
21		NaH
K2CO3
Et3N		1,4-dioxane60-
-
17		-
-
4		-
-
83:17
22Et3N9015384:16
Table 2. Experimentally obtained reaction yield.
Table 2. Experimentally obtained reaction yield.
Lines Productη (%)Productη (%)4:6
1Method A4a746a--
24b416b--
34c756c--
44d766d--
54e686e--
64f656f--
7Method B4a456a3358:42
84b596b2274:26
94c486c3259:41
104d236d3550:50
114e356e3052:48
124f346f3254:46
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lapić, J.; Kuzman, I.; Frkanec, R.; Frkanec, L.; Djaković, S. Ferrocenoylation of Uracil Derivatives: Study of Reaction Regioselectivity and Biological Activity. Molecules 2026, 31, 1054. https://doi.org/10.3390/molecules31061054

AMA Style

Lapić J, Kuzman I, Frkanec R, Frkanec L, Djaković S. Ferrocenoylation of Uracil Derivatives: Study of Reaction Regioselectivity and Biological Activity. Molecules. 2026; 31(6):1054. https://doi.org/10.3390/molecules31061054

Chicago/Turabian Style

Lapić, Jasmina, Ivana Kuzman, Ruža Frkanec, Leo Frkanec, and Senka Djaković. 2026. "Ferrocenoylation of Uracil Derivatives: Study of Reaction Regioselectivity and Biological Activity" Molecules 31, no. 6: 1054. https://doi.org/10.3390/molecules31061054

APA Style

Lapić, J., Kuzman, I., Frkanec, R., Frkanec, L., & Djaković, S. (2026). Ferrocenoylation of Uracil Derivatives: Study of Reaction Regioselectivity and Biological Activity. Molecules, 31(6), 1054. https://doi.org/10.3390/molecules31061054

Article Metrics

Back to TopTop